-
LBA3 Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study
N. Colombo, E. Zsiros, Alexandra Sebastianelli, Mariusz Bidziński, Emad Matanes, K. Hasegawa, +12 more
26citations -
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆2021 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer Genomics and Diagnostics Open access
Carsten Denkert, Michael Untch, Stephen Charles Benz, Andreas Schneeweiß, Karsten Ernst Weber, Sabine Schmatloch, +22 more
23citations -
ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
Evert S.M. van Aken, Bharti Devnani, Arsela Prelaj, Luís Castelo-Branco, Corrie A.M. Marijnen, Diogo Alexandre Martins-Branco, +21 more
22citations -
727TiP A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-32022 Annals of Oncology article Medicine Hepatocellular Carcinoma Treatment and Prognosis Open access
Ghassan K. Abou-Alfa, Junbai Fan, Jeong Heo, Y. Arai, J.P. Erinjeri, Christiane Katharina Kuhl, +4 more
19citations -
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer-related gene regulation Open access
M.M. Gounder, Patricia Martín-Romano, Antoîne Italiano, L. L. Siu, Philippe Alexandre Cassier, Gerald Steven Falchook, +15 more
17citations -
LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
Solange Peters, Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma, +12 more
16citations -
Outcome without any adjuvant systemic treatment in stage I ER+/HER2− breast cancer patients included in the MINDACT trial2021 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Josephine Lopes Cardozo, Danalyn Byng, Caroline A. Drukker, Marjanka K. Schmidt, Mary Ann E. Binuya, Laura van ‘t Veer, +5 more
16citations -
603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation2024 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Chromatin Remodeling and Cancer Open access
Robin Guo, Afshin Dowlati, Ibiayi Dagogo‐Jack, Julien Vibert, Alexander I. Spira, Victor Moreno Garcia, +12 more
15citations -
456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors2022 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer-related gene regulation Open access
S. Postel-Vinay, Antoîne Italiano, Philippe Alexandre Cassier, L.L. Siu, I. S. Lossos, J.F. Hilton, +13 more
15citations -
1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01
Mariana Brandão, J.T.J.N. Hiltermann, Els Wauters, Benjamin J. Solomon, Eduardo Castañón Álvarez, Enriqueta Felip, +12 more
12citations -
60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B
Jenny Furlanetto, Federick Marme, C. Thode, Valentina Nekljudova, Y. Liu, M. Martín Jiménez, +14 more
11citations -
LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Arnaud Scherpereel, Scott Joseph Antonia, Y. Bautista, Francesco Grossi, Dariusz Mirosław Kowalski, Gérard Zalcman, +11 more
11citations -
384O Laparoscopic versus open hemihepatectomy: The ORANGE II PLUS multicenter randomized controlled trial2021 Annals of Oncology article Medicine Hepatocellular Carcinoma Treatment and Prognosis Open access
Robert S. Fichtinger, Luca Antonio Aldrighetti, Roberto Ivan TROISI, Mohammad Abu Hilal, Robert Peter Sutcliffe, Marc G. Besselink, +14 more
9citations -
52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)2022 Annals of Oncology article Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access
A. Vogel, S. Boeck, O. Waidmann, Michael Bitzer, P. Wenzel, S. Belle, +13 more
9citations -
1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)2021 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access
Hans A. J. Gelderblom, Albiruni Ryan Abdul Razak, Amparo Sánchez-Gastaldo, Piotr Lukasz Rutkowski, Breelyn Ann Wilky, Michiel A. J. van de Sande, +5 more
8citations -
Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study
Matthijs van der Meulen, Katerina Bakunina, Marcel Nijland, Monique C. Minnema, Gavin Cull, Wendy B.C. Stevens, +10 more
7citations -
1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
Sapna Pradyuman Patel, Meredith Ann McKean, S. Piperno-Neumann, Alexander Noor Shoushtari, Leonel Fernando Hernandez-Aya, Marlana M. Orloff, +11 more
6citations -
138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial2022 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
JMS Bartlett, Keying Xu, Gregory R. Pond, Yi Zhang, Melanie Spears, Ranelle C. Salunga, +11 more
5citations -
Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial2026 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Olivia Pagani, Samuel M. Niman, Monica Ruggeri, Fedro Alessandro Peccatori, Hatem A. Azim, Marco Angelo Colleoni, +33 more
5citations